Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity
Aziz Mottiwala, insider at Tarsus Pharmaceuticals
Aziz Mottiwala Insider Alerts

Get notified the next time Aziz Mottiwala buys or sells Tarsus Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Aziz Mottiwala Insider Information

Aziz has over 20 years of biopharmaceutical industry leadership experience in several therapeutic areas, including over 10 years in the eye care space. Prior to joining Tarsus, Aziz was Chief Commercial Officer at Opiant Pharmaceuticals, overseeing all aspects of commercial strategy for the company’s addiction medicine portfolio. Before that, he was Senior Vice President and Head of Commercial at Avanir Pharmaceuticals. He also spent over 10 years at Allergan (an AbbVie company), most recently as Vice President of Marketing for the company’s eye care franchise, where he helped grow the business to over $2 billion in revenue across a diverse portfolio including Restasis® and Lumigan®, as well as several other devices and OTC product lines.

Previously, Aziz held commercial leadership roles at Valeant, IMS Health (now IQVIA), and Aventis Pharmaceuticals (now Sanofi). He received a BS in biochemistry from the University of California San Diego and an MBA in marketing and finance from the Marshall School of Business at the University of Southern California. He is also heavily active in the community and serves on the boards of the Orange County nonprofit OneOC and Octane.

What is Aziz Mottiwala's net worth?

The estimated net worth of Aziz Mottiwala is at least $1.61 million as of September 10th, 2021. Mr. Mottiwala owns 58,203 shares of Tarsus Pharmaceuticals stock worth more than $1,605,239 as of November 30th. This net worth approximation does not reflect any other assets that Mr. Mottiwala may own. Learn More.

How old is Aziz Mottiwala?

Mr. Mottiwala is currently 43 years old. There are 4 older executives and no younger executives at Tarsus Pharmaceuticals. The oldest executive at Tarsus Pharmaceuticals is Mr. Michael Holdbrook, VP of Clinical Affairs, who is 68 years old. Learn More.

How do I contact Aziz Mottiwala?

The corporate mailing address for Mr. Mottiwala and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at [email protected]

Has Aziz Mottiwala been buying or selling shares of Tarsus Pharmaceuticals?

Over the course of the past ninety days, Aziz Mottiwala has sold $216,583.00 in Tarsus Pharmaceuticals stock. Most recently, Aziz Mottiwala sold 1,889 shares of the business's stock in a transaction on Monday, November 8th. The shares were sold at an average price of $28.11, for a transaction totalling $53,099.79.

Who are Tarsus Pharmaceuticals' active insiders?

Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), and Aziz Mottiwala (Insider).

Are insiders buying or selling shares of Tarsus Pharmaceuticals?

During the last year, insiders at the sold shares 21 times. They sold a total of 630,182 shares worth more than $18,687,971.25. The most recent insider tranaction occured on November, 8th when insider Aziz Mottiwala sold 1,889 shares worth more than $53,099.79. Insiders at Tarsus Pharmaceuticals own 33.1 % of the company.

Information on this page was last updated on 11/8/2021.

Aziz Mottiwala Insider Trading History at Tarsus Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2021Sell1,889$28.11$53,099.79View SEC Filing Icon  
11/4/2021Sell100$28.03$2,803.00View SEC Filing Icon  
11/2/2021Sell6,000$26.78$160,680.00View SEC Filing Icon  
9/10/2021Sell2,593$22.15$57,434.9558,203View SEC Filing Icon  
See Full Table

Aziz Mottiwala Buying and Selling Activity at Tarsus Pharmaceuticals

This chart shows Aziz Mottiwala's buying and selling at Tarsus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $27.58
Low: $24.65
High: $28.03

50 Day Range

MA: $24.99
Low: $21.21
High: $29.68

2 Week Range

Now: $27.58
Low: $21.00
High: $63.69


32,155 shs

Average Volume

44,772 shs

Market Capitalization

$570.27 million

P/E Ratio


Dividend Yield



Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing
The White House is scared of our country's lithium supply running out. That's why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company who's gobbling up land in the lithium-rich Nevada desert.
Exec-Order 14017 Could Send This Company Skyrocket